BG103853A - 5, 6, 7-trisubstituted 4-aminopyridol[2,3-d]pyrimidine compounds - Google Patents

5, 6, 7-trisubstituted 4-aminopyridol[2,3-d]pyrimidine compounds

Info

Publication number
BG103853A
BG103853A BG103853A BG10385399A BG103853A BG 103853 A BG103853 A BG 103853A BG 103853 A BG103853 A BG 103853A BG 10385399 A BG10385399 A BG 10385399A BG 103853 A BG103853 A BG 103853A
Authority
BG
Bulgaria
Prior art keywords
compound
aminopyridol
trisubstituted
pyrimidine compounds
therapeutically effective
Prior art date
Application number
BG103853A
Other languages
Bulgarian (bg)
Inventor
Shripad Bhagwat
Richard Perner
Yu GU
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of BG103853A publication Critical patent/BG103853A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention relates to a compound with the formula where R1, R2, R3, R4 & R5 have the meanings listed in the description, to a method for adenosinekinase inhibition by the application of the compound, and to pharmaceutical composition containing therapeutically effective quantity of it in combination with a pharmaceutically acceptable carrier. The invention also relates to a method for the treatment of cerebral ischaemia, epilepsy, pain, feeling for injury, inflammation and sepsis in mammals where a therapeutically effective quantity of such a compound is applied, and to methods for its preparation. 19 claims
BG103853A 1997-04-16 1999-11-03 5, 6, 7-trisubstituted 4-aminopyridol[2,3-d]pyrimidine compounds BG103853A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84348497A 1997-04-16 1997-04-16
PCT/US1998/007201 WO1998046604A1 (en) 1997-04-16 1998-04-13 5,6,7-trisubstituted-4-aminopyridol[2,3-d]pyrimidine compounds

Publications (1)

Publication Number Publication Date
BG103853A true BG103853A (en) 2000-06-30

Family

ID=25290123

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103853A BG103853A (en) 1997-04-16 1999-11-03 5, 6, 7-trisubstituted 4-aminopyridol[2,3-d]pyrimidine compounds

Country Status (19)

Country Link
EP (1) EP0975633A1 (en)
JP (1) JP2001520654A (en)
KR (1) KR20010006462A (en)
CN (1) CN1252069A (en)
AR (1) AR012437A1 (en)
AU (1) AU741033B2 (en)
BG (1) BG103853A (en)
BR (1) BR9809056A (en)
CA (1) CA2286592A1 (en)
CO (1) CO4940470A1 (en)
HU (1) HUP0001443A3 (en)
IL (1) IL131617A0 (en)
NO (1) NO995035L (en)
NZ (1) NZ337125A (en)
PL (1) PL336265A1 (en)
SK (1) SK140099A3 (en)
TR (1) TR199902550T2 (en)
WO (1) WO1998046604A1 (en)
ZA (1) ZA983175B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057040A1 (en) * 2000-02-03 2001-08-09 Abbott Laboratories 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
ATE305303T1 (en) 2001-02-12 2005-10-15 Hoffmann La Roche 6-SUBSTITUTED PYRIDOPYRIMIDINES
CN107744520A (en) * 2017-10-25 2018-03-02 南京多宝生物科技有限公司 Pyrimidines are preparing the application in promoting small bowel peristalsis medicine
CN112209924B (en) * 2019-07-09 2022-04-05 中国科学院天津工业生物技术研究所 Selective adenosine A1Receptor antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB774094A (en) * 1953-01-02 1957-05-08 Wellcome Found Improvements in or relating to pyrimidine compounds
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds

Also Published As

Publication number Publication date
CO4940470A1 (en) 2000-07-24
CA2286592A1 (en) 1998-10-22
IL131617A0 (en) 2001-01-28
EP0975633A1 (en) 2000-02-02
WO1998046604A1 (en) 1998-10-22
AR012437A1 (en) 2000-10-18
ZA983175B (en) 1998-10-21
AU741033B2 (en) 2001-11-22
NZ337125A (en) 2001-06-29
TR199902550T2 (en) 2000-04-21
AU7108098A (en) 1998-11-11
HUP0001443A3 (en) 2001-01-29
SK140099A3 (en) 2000-05-16
KR20010006462A (en) 2001-01-26
PL336265A1 (en) 2000-06-19
CN1252069A (en) 2000-05-03
JP2001520654A (en) 2001-10-30
NO995035D0 (en) 1999-10-15
HUP0001443A2 (en) 2000-10-28
NO995035L (en) 1999-12-15
BR9809056A (en) 2000-08-01

Similar Documents

Publication Publication Date Title
MY121047A (en) Bicyclo [2.2.1] heptanes and related compounds
BG103417A (en) Condensed pyrimidine bicyclic derivatives
UA66825C2 (en) Azapolycyclic compounds condensed with aryl
HUP9901215A3 (en) Microemulsions for use as vehicles for administration of active compounds
CA2401229A1 (en) Aryl fused azapolycyclic compounds
CA2150123A1 (en) Aminomethylene substituted non-aromatic heterocycles
CA2258548A1 (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
YU11501A (en) 4,4-biarylpiperidine derivatives with opioid receptor activity
HUP0002956A3 (en) Use of 4-aminopyrrole[3,2d]pyrimidines for the preparation of pharmaceutical compositions treating diseases related to an excess of neuropeptide y
JO2285B1 (en) Dihydro-benzo (b) (1.4) dizepin-2-one derivatives as mglur2 antagonists ii
CA2293823A1 (en) 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
WO2001078711A3 (en) Pde-v inhibitors for treatment of parkinson's disease
TW200500344A (en) Novel compounds
YU79103A (en) Dihydro-benzo/b/ /1,4/diazepin-2-one derivatives as mglur2 antagonists i
UA42738C2 (en) Derivatives of 1,2,4-triazolo[1,5-a]pyrimidines, pharmaceutical composition containing them, method for inhibition of seizures
HUP0003982A3 (en) The use of inhibitors of the renin-angiotensin system for producing pharmaceutical compositions using for the treatment of hypoxia or impaired metabolic function
CA2108903A1 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
BG103842A (en) 5,7-disubstituted 4-aminopyrido [2,3-d]pyrimidine compounds and their application as adenosinekinase inhibitors
AP2001002191A0 (en) 3,3- Biarylpiperine and 2,2-biarylmorpholine derivatives.
AU5884496A (en) Therapeutic sepsis treatment using antagonists to pthrp
BG103853A (en) 5, 6, 7-trisubstituted 4-aminopyridol[2,3-d]pyrimidine compounds
BG103861A (en) 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
PL338680A1 (en) 8-substituted derivatives of 9-h-1,3-dioxolo/4,5-h/2,3-benzoidazepins as inhibitors of ampa/cainate receptors
MY118244A (en) Alfa-amino acid amides, preparation thereof and the therapeutical use thereof
ES2005042A6 (en) Anticonvulsant composition containing amino acid derivative and use of said amino acid derivative.